Individualized Treatment Approaches in Patients with Newly Diagnosed Hodgkin Lymphoma

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: September 10, 2018
Expiration Date: September 10, 2019

Expected time to complete this activity as designed: 15 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

The management of patients with newly diagnosed Hodgkin lymphoma (HL) continues to evolve as new therapies and treatment approaches are being investigated and introduced. This activity will review helpful, evidence-based strategies for individualizing therapy in the frontline setting by describing emerging treatment regimens for newly diagnosed HL and the latest clinical data regarding these options.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including primary care physicians, hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with Hodgkin lymphoma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe new and emerging agents for treatment of HL in the frontline setting
  • Explain the latest clinical data regarding the efficacy and safety of emerging agents for newly diagnosed patients with HL
  • Incorporate evidence-based recommendations for treatment into therapeutic strategies for patients with newly diagnosed HL

Agenda

Individualized Treatment Approaches in Patients with Newly Diagnosed Hodgkin Lymphoma – Alison J. Moskowitz, MD

Instructions for Participation and Credit

This activity is eligible for credit through September 10, 2019. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Alison J. Moskowitz, MD
Clinical Director, Lymphoma Inpatient Unit
Assistant Attending, Lymphoma Service
Memorial Sloan Kettering Cancer Center
New York, New York

Dr. Alison Moskowitz received her medical degree from Albert Einstein College of Medicine in the Bronx. She completed her internal medicine residency and internship at Columbia University Medical Center, followed by hematology/medical oncology fellowships at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York City. Dr. Moskowitz is Clinical Director of the Lymphoma Inpatient Unit, and Assistant Attending, Lymphoma Service, at Memorial Sloan Kettering Cancer Center in New York.

Dr. Moskowitz is board certified in internal medicine, medical oncology, and hematology. She holds professional membership in the American Medical Association (AMA), the American Society of Clinical Oncology (ASCO), and the American Society of Hematology (ASH). Dr. Moskowitz has lectured and authored/co-authored peer-reviewed articles on autologous stem cell transplantation, relapsed/refractory Hodgkin lymphoma, and T-cell lymphoma. Her primary research focus is on evaluating novel treatments for Hodgkin lymphoma.

Accreditation

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.25 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-18-022-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

Disclosures

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Alison Moskowitz has received honoraria as a consultant from Cell Medica, Kyowa Hakko Kirin Co., Ltd., and Seattle Genetics, Inc.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Andrea Mathis, Project Manager, Keith D’Oria, Medical Writer, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at lisa@medicaled.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb, Merck & Co., Inc., and Seattle Genetics, Inc.

©2018 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Managing HL would like to recognize and thank Bristol-Myers Squibb, Merck & Co., Inc., and Seattle Genetics for their educational support of ManagingHodgkinLymphoma.com in 2018.

©2018 MediCom Worldwide, Inc. All rights reserved